OPKO Health, Inc.

Symbol: OPK

NASDAQ

1.26

USD

Market price today

  • -3.5276

    P/E Ratio

  • -0.0415

    PEG Ratio

  • 878.21M

    MRK Cap

  • 0.00%

    DIV Yield

OPKO Health, Inc. (OPK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.33%

Operating Profit Margin

-0.25%

Net Profit Margin

-0.32%

Return on Assets

-0.13%

Return on Equity

-0.18%

Return on Capital Employed

-0.11%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO:Dr. Phillip Frost Ph.D.
Full-time employees:3930
City:Miami
Address:4400 Biscayne Boulevard
IPO:1995-11-02
CIK:0000944809

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

General Outlook

When we look at how much money they make before expenses, they keep 0.327% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.248%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.316%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.128% return, is a testament to OPKO Health, Inc.'s adeptness in optimizing resource deployment. OPKO Health, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.180%. Furthermore, the proficiency of OPKO Health, Inc. in capital utilization is underscored by a remarkable -0.112% return on capital employed.

Stock Prices

OPKO Health, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.28, while its low point bottomed out at $1.22. This variance in figures offers investors a lucid insight into the roller-coaster ride that is OPKO Health, Inc.'s stock market.

Liquidity Ratios

Analyzing OPK liquidity ratios reveals its financial health of the firm. The current ratio of 191.50% gauges short-term asset coverage for liabilities. The quick ratio (91.52%) assesses immediate liquidity, while the cash ratio (37.02%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio191.50%
Quick Ratio91.52%
Cash Ratio37.02%

Profitability Ratios

OPK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -31.33% underscores its earnings before tax deductions. The effective tax rate stands at -1.84%, revealing its tax efficiency. The net income per EBT, 100.78%, and the EBT per EBIT, 126.57%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -24.76%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-31.33%
Effective Tax Rate-1.84%
Net Income per EBT100.78%
EBT per EBIT126.57%
EBIT per Revenue-24.76%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.91, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding92
Days of Inventory Outstanding40
Operating Cycle91.08
Days of Payables Outstanding48
Cash Conversion Cycle43
Receivables Turnover7.18
Payables Turnover7.57
Inventory Turnover9.07
Fixed Asset Turnover6.27
Asset Turnover0.41

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.06, and free cash flow per share, -0.08, depict cash generation on a per-share basis. The cash per share value, 0.11, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.05, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.06
Free Cash Flow per Share-0.08
Cash per Share0.11
Operating Cash Flow Sales Ratio-0.05
Free Cash Flow to Operating Cash Flow Ratio1.43
Cash Flow Coverage Ratio-0.10
Short Term Coverage Ratio-1.18
Capital Expenditure Coverage Ratio-2.33
Dividend Paid and Capex Coverage Ratio-2.33

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 21.78%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.34, we discern the balance between debt and equity financing. The long-term debt to capitalization, 23.98%, and total debt to capitalization, 25.55%, ratios shed light on its capital structure. An interest coverage of 45.61 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio21.78%
Debt Equity Ratio0.34
Long Term Debt to Capitalization23.98%
Total Debt to Capitalization25.55%
Interest Coverage45.61
Cash Flow to Debt Ratio-0.10
Company Equity Multiplier1.58

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.15, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.25, reflects the portion of profit attributed to each share. The book value per share, 1.85, represents the net asset value distributed per share, while the tangible book value per share, -0.19, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.15
Net Income Per Share-0.25
Book Value Per Share1.85
Tangible Book Value Per Share-0.19
Shareholders Equity Per Share1.85
Interest Debt Per Share0.37
Capex Per Share-0.02

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -14.01%, indicates top-line expansion, while the gross profit growth, -19.47%, reveals profitability trends. EBIT growth, 35.80%, and operating income growth, 35.80%, offer insights into operational profitability progression. The net income growth, 42.42%, showcases bottom-line expansion, and the EPS growth, 45.65%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-14.01%
Gross Profit Growth-19.47%
EBIT Growth35.80%
Operating Income Growth35.80%
Net Income Growth42.42%
EPS Growth45.65%
EPS Diluted Growth45.65%
Weighted Average Shares Growth4.55%
Weighted Average Shares Diluted Growth4.55%
Operating Cash Flow Growth70.38%
Free Cash Flow Growth62.87%
10-Year Revenue Growth per Share322.53%
5-Year Revenue Growth per Share-34.68%
3-Year Revenue Growth per Share-48.73%
10-Year Operating CF Growth per Share77.11%
5-Year Operating CF Growth per Share80.65%
3-Year Operating CF Growth per Share-160.87%
10-Year Net Income Growth per Share22.02%
5-Year Net Income Growth per Share7.53%
3-Year Net Income Growth per Share-626.22%
10-Year Shareholders Equity Growth per Share-25.13%
5-Year Shareholders Equity Growth per Share-41.90%
3-Year Shareholders Equity Growth per Share-29.18%
10-Year Dividend per Share Growth per Share-100.00%
Receivables Growth-12.39%
Inventory Growth-11.29%
Asset Growth-7.18%
Book Value per Share Growth-14.91%
Debt Growth52.96%
R&D Expense Growth21.24%
SGA Expenses Growth-19.36%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,365,849,531.65, captures the company's total value, considering both debt and equity. Income quality, 0.15, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 76.23%, indicates the value of non-physical assets, and capex to operating cash flow, 57.72%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value1,365,849,531.65
Income Quality0.15
Research and Development to Revenue10.38%
Intangibles to Total Assets76.23%
Capex to Operating Cash Flow57.72%
Capex to Revenue-1.88%
Capex to Depreciation-15.46%
Stock-Based Compensation to Revenue1.32%
Graham Number3.23
Return on Tangible Assets-39.50%
Graham Net Net-0.53
Working Capital109,424,000
Tangible Asset Value-144,324,000
Net Current Asset Value-313,003,000
Average Receivables139,403,999.5
Average Payables68,338,500
Average Inventory69,878,500
Days Sales Outstanding55
Days Payables Outstanding40
Days of Inventory On Hand38
ROIC-9.78%
ROE-0.14%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.71, and the price to book ratio, 0.71, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.10, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -14.94, and price to operating cash flows, -21.66, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio0.71
Price to Book Ratio0.71
Price to Sales Ratio1.10
Price Cash Flow Ratio-21.66
Price Earnings to Growth Ratio-0.04
Enterprise Value Multiple-3.58
Price Fair Value0.71
Price to Operating Cash Flow Ratio-21.66
Price to Free Cash Flows Ratio-14.94
Price to Tangible Book Ratio0.82
Enterprise Value to Sales1.58
Enterprise Value Over EBITDA-25.89
EV to Operating Cash Flow-48.44
Earnings Yield-16.64%
Free Cash Flow Yield-3.92%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of OPKO Health, Inc. (OPK) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.528 in 2024.

What is the ticker symbol of OPKO Health, Inc. stock?

The ticker symbol of OPKO Health, Inc. stock is OPK.

What is company IPO date?

IPO date of OPKO Health, Inc. is 1995-11-02.

What is company current share price?

Current share price is 1.260 USD.

What is stock market cap today?

The market cap of stock today is 878209920.000.

What is PEG ratio in 2024?

The current -0.042 is -0.042 in 2024.

What is the number of employees in 2024?

In 2024 the company has 3930.